Local enema treatment to inhibit FOLH1 /GCPII as a novel therapy for inflammatory bowel disease-Reference-Cited by-同舟云学术

Local enema treatment to inhibit FOLH1 /GCPII as a novel therapy for inflammatory bowel disease

Published:2017-10 Issue: Volume:263 Page:132-138
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Date Abhijit A.,Rais Rana,Babu Taarika,Ortiz Jairo,Kanvinde Pranjali,Thomas Ajit G.,Zimmermann Sarah C.,Gadiano Alexandra J.,Halpert Gilad,Slusher Barbara S.,Ensign Laura M.

Funder

NIH

Sanofi

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference47 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease;Xavier;Nature,2007

2. The fundamental basis of inflammatory bowel disease;Strober;J. Clin. Invest.,2007

3. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis;Sartor;Nat. Clin. Pract. Gastroenterol. Hepatol.,2006

4. Inflammatory bowel disease;Kaser;Annu. Rev. Immunol.,2010

5. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance;Hamilton;J. Gastroenterol.,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutamate carboxypeptidase II;Metalloenzymes;2024

2. PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease;Clinical and Experimental Gastroenterology;2023-12

3. A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis;Science Translational Medicine;2023-08-09

4. Pediatric Crohn's disease diagnosis aid via genomic analysis and machine learning;Frontiers in Pediatrics;2023-03-23

5. Targeting pathophysiological changes using biomaterials-based drug delivery systems: A key to managing inflammatory bowel disease;Frontiers in Pharmacology;2022-11-10